Antic, Darko (23979576100)Darko (23979576100)AnticMihaljevic, Biljana (6701325767)Biljana (6701325767)MihaljevicCokic, Vladan (6507196877)Vladan (6507196877)CokicFekete, Marija Dencic (36652618600)Marija Dencic (36652618600)FeketeDjurasevic, Teodora Karan (41661218400)Teodora Karan (41661218400)DjurasevicPavlovic, Sonja (7006514877)Sonja (7006514877)PavlovicMilic, Natasa (7003460927)Natasa (7003460927)MilicElezovic, Ivo (12782840600)Ivo (12782840600)Elezovic2025-07-022025-07-022011https://doi.org/10.3109/10428194.2011.578311https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959613190&doi=10.3109%2f10428194.2011.578311&partnerID=40&md5=d582e54a93a6c4c2841467a039d36958https://remedy.med.bg.ac.rs/handle/123456789/14070We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of β2-microglobulin (β2M) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of β2M, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p < 0.0001). © 2011 Informa UK, Ltd.Lymphoma and Hodgkin diseasemolecular geneticsprognostication